Psychopharmacology - Articles - Page 5

Research Theme Park: Medland

April 20, 2020

Lithium takes on the coronavirus. Benzos impair facial recognition. Antipsychotic doses find their maximum, the profile of a lithium responder, and topiramate for compulsive shopping.Published On: 4/21/20Duration: 13 minutes, 51 secondsStudies Referenced: Garcez H, Fernandes C, Barbosa F, et al. Effects of benzodiazepines administration on identification of facial expressions of...

7 Clozapine Tips

April 8, 2020

We're supposed to move to clozapine after two failed antipsychotics in schizophrenia, but how many of us are really doing that? Not enough. Clozapine may be difficult to use, but it is life changing for many patients. Here we bring you 7 tips, from serum plasma levels to little-known side...

How to Dose an Antidepressant

April 3, 2020

Some antidepressants get better as the dose goes higher, while others just fizzle. For older patients, the side effects stack up as the benefits plateau. We review 3 new meta-analyses on antidepressant dosing, and bring you 4 updates on how the coronavirus is changing practice regulation.Date Published: 3/30/2020Duration: 27 minutes,...

How to Choose an Antipsychotic in Schizophrenia

March 30, 2020

Rehan Aziz, MD.

Rehan Aziz, MD. Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Atypical antipsychotics are more alike than different, but a few stand out for tolerability, while others may have an edge for negative symptoms or for overall efficacy.

The Psychopharmacology Algorithm Project

March 30, 2020

David Osser, MD

David Osser, MD

General Editor of the Psychopharmacology Algorithm Project at the Harvard South Shore Psychiatry Residency Training Program and Associate Professor of Psychiatry at Harvard University. Dr. Osser has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. Osser set out to develop a psychopharmacology algorithm that actually changes practice. He speaks to us on antidepressants in bipolar, psychoses that don’t need antipsychotics, and his top picks for bipolar mania, bipolar depression, and unipolar depression.

Oxcarbazepine: Close, but no Cigar

March 9, 2020

Oxcarbazepine is thought of as a kinder, gentler cousin of carbamazepine, but it brings new safety issues of its own and does not fully escape the drug interactions that hinder carbamazepine. We pull on the published and unpublished trials to figure out where this anticonvulsant stands in bipolar disorder.

Lumateperone and lemborexant

March 9, 2020

The antipsychotic lumateperone (Caplyta) and the hypnotic lemborexant (Dayvigo) are the newest in their class. Both of them claim to improve on the safety of older medications, and we look at the data to see how those claims hold up.

Highlight From This Issue

March 9, 2020

Quick summary of the issue.

The Medication Fact Book for Psychiatric Practice, Fifth Edition (2020)

PDF Access and CME Post-Test

February 29, 2020

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have disclosed that they has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

This page has links and instructions for downloading your PDF and eBook copies of The Medication Fact Book for Psychiatric Practice, Fifth Edition (2020) and completing the 12 CME Post-Test.

How to Treat Tardive Dyskinesia

January 13, 2020

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The VMAT2 inhibitors are FDA approved for tardive dyskinesia (TD), but there are 8 off-label options to consider as well. See how they stack up here, and learn why the atypical antipsychotics ─ with one exception ─ have not put an end to this insidious side effect.